Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of FB704A in Rheumatoid Arthritis
NCT03890302Phase 1Completed
- Sponsor
- Fountain Biopharma Inc.
- Start
- Mar 2019
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FB 704A in rheumatoid arthritis (RA) (5 cohorts), sponsored by Fountain Biopharma Inc. Primary endpoints: Incidence of Adverse Events (Part 1) at Day 57, Incidence of Adverse Events (Part 2) at Day 99 and 6 more. Started Mar 2019; status: completed.
02
Drugs
FB 704A
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03890302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03890302.